Current and prospective shareholders of Harris & Harris Group,
Inc. (NASDAQ:TINY) may be interested in a number of announcements
by some of our portfolio companies during the third quarter of
2016. These announcements, as well as news from our other
portfolio companies, can be found on our website at www.hhvc.com.
D-Wave Systems, Inc.
On September 27, 2016, D-Wave Systems announced
details of its most advanced quantum computing system, featuring a
new 2,000 qubit processor. The company made the announcement
at its inaugural users group conference in Santa Fe, New
Mexico. The company’s press release may be found at
http://www.dwavesys.com/press-releases/d-wave-systems-previews-2000-qubit-quantum-system.
This announcement was also covered in a number of press articles
including:
- International Business Times - “D-Wave Systems Announces 2,000
Qubit Quantum Annealing Computers, Says It is 1,000 Times Faster
Than Predecessor.”
(http://www.ibtimes.com/d-wave-systems-announces-2000-qubit-quantum-annealing-computer-says-it-1000-times-2423682)
- Yahoo Finance - “In Quantum Computing Advance, D-Wave Announces
2,000 Qubit Processor”
(https://www.yahoo.com/tech/d-wave-claims-latest-quantum-172219198.html?soc_src=mail&soc_trk=ma)
- PC World - “D-Wave Will Ship a 2,000-Qubit Quantum Computer
Next Year”
(http://www.pcworld.com/article/3122452/hardware/d-wave-will-ship-a-2000-qubit-quantum-computer-next-year.html)
HZO, Inc.
On August 17, 2016, HZO announced a
collaboration with Rakuten Kobo to protect its latest eReader, the
Kobo Aura ONE. The company’s press release may be found at
http://www.hzo.com/rakuten-kobo-chooses-hzo-to-waterproof-its-next-generation-ereader-the-kobo-aura-one/.
Precision Health and
Medicine
The following announcements were made by
companies we are building that are focused on precision health and
medicine.
Interome, Inc.
On August 15, 2016, Interome announced that it
was a co-organizer of the UnDx Consortium™. This organization
brings together five precision medicine technology providers and
prominent experts from medical centers and universities across the
country to collaborate in an effort to produce new hypotheses for a
set of six patients struggling with undiagnosed diseases. The
UnDx Consortium met to explore results of cutting-edge tests
analyzing samples from these patients and their families.
That meeting was the beginning of what is expected to evolve into
an ongoing forum to explore the potential of combining precision
medicine technologies to diagnose and treat disease.
Interome’s press release may be viewed at
https://globenewswire.com/news-release/2016/08/15/864246/0/en/Precision-Medicine-Put-to-the-Test-UnDx-Consortium-Gathers-to-Examine-New-Hypotheses-for-Undiagnosed-Patients.html.
A number of Harris & Harris Group’s companies focused on
precision health and medicine participated in the event including
Muses Labs, Inc., Metabolon, Inc., and ORIG3N, Inc.
On September 26, 2016, Interome announced that
collaborators and organizers of the UnDx Consortium would come
together again at the 14th annual Future in Review (FiRe)
conference. The conversation would include a summary of the UnDx
Consortium, a discussion of hypotheses resulting from analyzation
of data from the Consortium on August 16, 2016, and proposed next
steps for the UnDx Consortium. The FiRe conference was held
September 27 – 30, 2016 in Park City, Utah. Interome’s press
release may be viewed at
https://globenewswire.com/news-release/2016/09/26/874582/0/en/UnDx-Consortium-to-Present-at-14th-Annual-Future-in-Review-Conference.html.
On July 25, 2016, Doug Jamison, Chairman of
Interome and Chairman and Chief Executive Officer of Harris &
Harris Group, collaborated with Katia Moritz, a Board Certified
physician, to author an article entitled, “Can the Gut Microbiome
Be Used to Provide Valuable Information to Undiagnosed Patients?”
This article was published on the website of the American Gut
Project, a study co-founded by Dr. Rob Knight and Jeff Leach, that
enables participants to learn about their own body’s microbes while
also contributing to the greater scientific effort to learn how the
human microbiome is associated with various aspects of our
health--from associations with diet to the amount of alcohol
someone drinks to whether or not someone has autism or IBD.
The article may be viewed at
http://americangut.org/can-the-gut-microbiome-be-used-to-provide-valuable-information-to-undiagnosed-patients/#.
Muses Labs, Inc.
On September 2, 2016, Muses Labs presented data
from a pilot study of its MEND Protocol for the treatment of early
Alzheimer’s disease at the Alzheimer’s Association International
Conference 2016. MEND Protocol is a multi-step cognitive
evaluation process that uses advanced data processing technology to
first assess which risk factors are present in an individual.
Muses Labs’ press release may be viewed at
https://alzheimersnewstoday.com/2016/09/02/muses-labs-pilot-study-of-alzheimers-mend-protocol-shows-promise-in-at-risk-people/.
On July 13, 2016, Muses Labs and Metabolon,
another portfolio company of Harris & Harris Group, announced a
partnership to study and apply metabolomics in individuals with
pre- and early-symptomatic cognitive decline and Alzheimer’s
disease. The companies stated that they expect to bring new
clinical trial services and updated care protocols to the market in
2016. The joint press release may be viewed at
https://museslabs.com/metabolon-and-muses-labs-partner-to-apply-metabolomics-to-alzheimers-disease/.
Metabolon, Inc.
On August 11, 2016, Metabolon announced that it
closed a round of financing of $15 million from a new investor,
Essex Woodlands. The company’s press release may be viewed at
http://www.metabolon.com/news-2016/metabolon-closes-$15-million-financing-to-support-precision-medicine-growth-opportunities.aspx.
On September 28, 2016, Metabolon announced that
it launched its Meta IMDTM test for diagnosis of inherited
metabolon disorders. The company’s press release may be
viewed at
http://www.metabolon.com/news-2016/metabolon-launches-meta-imd-test-to-speed-diagnosis-of-inherited-metabolic-disorders.aspx.
EchoPixel, Inc.
On July 21, 2016, EchoPixel announced that its
medical virtual reality system is ready for clinical
implementation. The system is being distributed to customers
in collaboration with the HP Zvr Interactive Virtual Reality
Display and workstation. The company’s press release may be
viewed at
http://www.marketwired.com/press-release/echopixel-medical-virtual-reality-system-ready-for-clinical-implementation-2144398.htm.
On September 28, 2016, EchoPixel’s 3D
visualization technology was profiled in an article and video by
ABC News. The article and video can be viewed at
http://abc7news.com/health/ucsf-doctors-use-virtual-screenings-to-save-lives/1530980/.
Harris & Harris Group is a publicly traded,
internally managed business development company that builds
transformative companies from disruptive science. Detailed
information about Harris & Harris Group and its holdings can be
found on its website at www.HHVC.com, on Facebook at
www.facebook.com/harrisharrisvc and by following on Twitter
@harrisandharrisgroup.
This press release may contain statements of a
forward-looking nature relating to future events. These
forward-looking statements are subject to the inherent
uncertainties in predicting future results and conditions. These
statements reflect the Company's current beliefs, and a number of
important factors could cause actual results to differ materially
from those expressed in this press release. Please see the
Company's Annual Report on Form 10-K for the fiscal year ended
December 31, 2015, as well as subsequent filings, filed with the
Securities and Exchange Commission for a more detailed discussion
of the risks and uncertainties associated with the Company's
business, including, but not limited to, the risks and
uncertainties associated with venture capital investing and other
significant factors that could affect the Company's actual results.
Except as otherwise required by Federal securities laws, the
Company undertakes no obligation to update or revise these
forward-looking statements to reflect new events or
uncertainties. The references to the websites www.HHVC.com,
www.dwavesys.com, www.hzo.com, www.metabolon.com,
www.museslabs.com, www.americangut.org,
www.alzheimersnewstoday.com, www.globenewswire.com,
www.pcworld.com, www.yahoo.com, www.ibtimes.com, www.echopixel.com,
www.marketwired.com, www.abc7news.com, www.museslabs.com and
www.Facebook.com have been provided as a convenience, and the
information contained on such websites is not incorporated by
reference into this press release. Harris & Harris Group
is not responsible for the contents of third party websites.
Company Contact:
Daniel B. Wolfe
Harris & Harris Group, Inc.
President
(212) 582-0900
180 Degree Capital (NASDAQ:TURN)
Historical Stock Chart
From Mar 2024 to Apr 2024
180 Degree Capital (NASDAQ:TURN)
Historical Stock Chart
From Apr 2023 to Apr 2024